Lenacapavir (Sunlenca) (tabs and injection)

Status:

Do Not Prescribe (DNP)

Decision Date:

November 2022

Comments

Use in combination with other antiretroviral(s) for the treatment of adults with multidrug‑resistant HIV‑1 infection for whom it is otherwise not possible to construct a suppressive anti‑viral regimen 

Black Drug Classifications

• 2: Have a lack of data on safety compared with standard therapy
• 4: Have a lack of data on cost-effectiveness compared with standard therapy
• 5: Less cost-effective than current standard therapy

search again